Medicare billing address
CMS Medicare provider billing file
5734 S 1475 E Ste 300Ogden, UT 84403
CMS public data · NPI 1114098357
CMS public files list billing, prescribing, location, and participation fields for this NPI. Current plan networks, appointment availability, clinical outcomes, and patient-specific medical advice require separate verification.
CMS display name
Julie A Maughan, MD
Specialty
Credential
MD
NPI
1114098357
Primary source state
UT
Data retrieval date
July 28, 2026
Where these numbers come from, and what they cannot tell you
Public CMS records, 2024 reporting year. These are historical Medicare fields, not proof of current coverage, appointment availability, quality, or what someone will pay.
This page shows Medicare billing and Part D prescribing data for Julie A Maughan, MD from CMS public files. It covers 2024 claims data: services billed, the beneficiary panel, and the most-prescribed Part D drugs. It does not show current coverage, appointment availability, or quality ratings.
A licensed agent, not a call center
Peter Abilla, Licensed Medicare Insurance Sales Agent, NPN 22265186. Bring the doctors and prescriptions that matter to you, then check the details before you enroll.
Medicare participating
Yes
Individual assignment
Yes
Group assignment
Yes
CMS opt-out records
0
When CMS files list more than one address for the same NPI, each address stays tied to the CMS file that reported it.
CMS Medicare provider billing file
5734 S 1475 E Ste 300CMS Doctors & Clinicians file
5734 S 1475In the 2024 CMS provider billing file, this NPI had 767 Medicare beneficiaries and 8,009 total services. The average beneficiary age was 76, and the average HCC risk score was 1.1.
Total Medicare allowed amount
$321,253.85
Total Medicare payment amount
$222,326.78
Medicare beneficiaries
767
Total services
8,009
These percentages describe the Medicare beneficiary panel in the CMS utilization file. They are not a diagnosis for any individual patient and are not a quality score.
Hyperlipidemia
67%
CMS beneficiary-panel share
Hypertension
67%
CMS beneficiary-panel share
Chronic kidney disease
25%
CMS beneficiary-panel share
Diabetes
23%
CMS beneficiary-panel share
Mood disorders
22%
CMS beneficiary-panel share
Depression
21%
CMS beneficiary-panel share
Where these service numbers come from, and what they cannot tell you
Amounts shown are average Medicare-approved amounts per billed unit in CMS records. What a person pays depends on current coverage and cannot be read from this table alone.
| CMS service description | Services | Avg allowed |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 4,774 | $6.51 |
| Destruction of precancer skin growth, 1 growth | 857 | $50.68 |
| Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | 841 | $90.21 |
| Biopsy of related skin growth, first growth | 527 | $93.90 |
| Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 182 | $127.84 |
| Biopsy of related skin growth, each additional growth | 174 | $49.08 |
| Destruction of precancer skin growth, 15 or more growths | 173 | $165.69 |
| Destruction of skin growth, 1-14 growths | 135 | $110.81 |
| Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more | 58 | $56.56 |
| New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more | 53 | $109.70 |
Where these Part D numbers come from, and what they cannot tell you
CMS data reports historical prescription drug events attributed to NPI 1114098357. Formularies, copays, prior authorization, and step therapy rules vary by current coverage.
| Rank | Drug | Generic name | Total claims | 30-day fills | Total drug cost |
|---|---|---|---|---|---|
| 1 | Triamcinolone Acetonide | Triamcinolone Acetonide | 102 | 130.7 | $945.14 |
| 2 | Fluorouracil | Fluorouracil | 81 | 93.7 | $5,643.08 |
| 3 | Nystatin | Nystatin | 77 | 78.2 | $808.06 |
| 4 | Ketoconazole | Ketoconazole | 65 | 83.3 | $1,193.85 |
| 5 | Clobetasol Propionate | Clobetasol Propionate | 58 | 75.2 | $3,208.09 |
| 6 | Valacyclovir | Valacyclovir Hcl | 45 | 56 | $587.78 |
| 7 | Famotidine | Famotidine | 32 | 60 | $473.35 |
| 8 | Montelukast Sodium | Montelukast Sodium | 32 | 47.3 | $140.55 |
| 9 | Clindamycin Phosphate | Clindamycin Phosphate | 30 | 35 | $769.43 |
| 10 | Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 33 | $324.22 |
CMS Part D records are historical aggregate claims data. They do not include current formulary status, pharmacy price, prior-authorization rules, network-directory status, or clinical-outcome data.
Medical school
University Of Southern California Keck School Of Medicine
Graduation year
2000
Group/practice field
Wasatch Dermatology Pc
Telehealth reported
Not reported
Verify plan-directory status, drug formulary rules, pharmacy pricing, appointment availability, and clinical questions against current plan documents and the relevant provider or care team.
The numbers above come from CMS public-use files for this NPI. Each link identifies the CMS release used and the retrieval date.